NRAS is mutated in 20.8% of melanoma patients [3].

NRAS is an inclusion criterion in 13 clinical trials for melanoma, of which 5 are open and 8 are closed. Of the trials that contain NRAS status and melanoma as inclusion criteria, 7 are phase 1 (3 open), 4 are phase 1/phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

Binimetinib has evidence of efficacy in patients with NRAS mutation in melanoma [4].

NRAS is mutated in 2.37% of malignant solid tumor patients [3].

NRAS is an inclusion criterion in 27 clinical trials for malignant solid tumor, of which 20 are open and 7 are closed. Of the trials that contain NRAS status and malignant solid tumor as inclusion criteria, 14 are phase 1 (9 open), 7 are phase 1/phase 2 (6 open), and 6 are phase 2 (5 open) [4].

NRAS is mutated in 4.03% of colorectal carcinoma patients [3].

NRAS is an inclusion criterion in 17 clinical trials for colorectal carcinoma, of which 14 are open and 3 are closed. Of the trials that contain NRAS status and colorectal carcinoma as inclusion criteria, 10 are phase 1 (9 open), 4 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [4].

NRAS is mutated in 1.01% of non-small cell lung carcinoma patients [3].

NRAS is an inclusion criterion in 11 clinical trials for non-small cell lung carcinoma, of which 9 are open and 2 are closed. Of the trials that contain NRAS status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

NRAS is mutated in 9.68% of acute myeloid leukemia patients [3].

NRAS is an inclusion criterion in 9 clinical trials for acute myeloid leukemia, of which 4 are open and 5 are closed. Of the trials that contain NRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), 4 are phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

NRAS is mutated in 2.29% of myelodysplastic syndromes patients [3].

NRAS is an inclusion criterion in 7 clinical trials for myelodysplastic syndromes, of which 4 are open and 3 are closed. Of the trials that contain NRAS status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

NRAS is mutated in 17.28% of chronic myelomonocytic leukemia patients [3].

NRAS is an inclusion criterion in 5 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain NRAS status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

NRAS is mutated in 0.91% of non-hodgkin lymphoma patients [3].

NRAS is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain NRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [4].

NRAS is an inclusion criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain NRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

NRAS is mutated in 12.5% of acute lymphoblastic leukemia patients [3].

NRAS is an inclusion criterion in 4 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 1 is closed. Of the trials that contain NRAS status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

NRAS is mutated in 4.05% of colorectal adenocarcinoma patients [3].

NRAS is an inclusion criterion in 4 clinical trials for colorectal adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain NRAS status and colorectal adenocarcinoma as inclusion criteria, 4 are phase 2 (4 open) [4].

NRAS is mutated in 0.72% of pancreatic carcinoma patients [3].

NRAS is an inclusion criterion in 4 clinical trials for pancreatic carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NRAS status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [4].

NRAS is mutated in 0.62% of glioma patients [3].

NRAS is an inclusion criterion in 4 clinical trials for glioma, of which 4 are open and 0 are closed. Of the trials that contain NRAS status and glioma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [4].

NRAS is mutated in 2.66% of cancer patients [3].

NRAS is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain NRAS status and cancer as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

NRAS is mutated in 2.07% of ovarian carcinoma patients [3].

NRAS is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 1 is open and 2 are closed. Of the trials that contain NRAS status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 3 clinical trials for neurofibromatosis type 1, of which 2 are open and 1 is closed. Of the trials that contain NRAS status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

NRAS is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

NRAS is mutated in 27.07% of poorly differentiated thyroid gland carcinoma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

NRAS is mutated in 0.93% of squamous cell lung carcinoma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

NRAS is mutated in 0.5% of breast carcinoma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [4].

NRAS is an inclusion criterion in 2 clinical trials for neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

NRAS is mutated in 18.45% of thyroid gland undifferentiated (anaplastic) carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is mutated in 14.56% of thyroid gland follicular carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is mutated in 11.96% of thyroid gland adenocarcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thyroid gland adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is mutated in 11.3% of thyroid gland carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is mutated in 7.75% of low grade ovarian serous adenocarcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is mutated in 7.64% of thyroid gland papillary carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is mutated in 8.0% of rhabdomyosarcoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is mutated in 4.41% of rectal carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is mutated in 4.19% of colon carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and colon carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is mutated in 3.74% of lymphoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is mutated in 2.77% of endometrial carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is mutated in 2.14% of soft tissue sarcoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is mutated in 1.44% of bladder carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is mutated in 1.32% of sarcoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is mutated in 0.79% of glioblastoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NRAS is mutated in 0.27% of prostate carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts-2, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and refractory anemia with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].